NCT02303912View on ClinicalTrials.gov

Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 23, 2017

Study Completion Date

January 23, 2017

Conditions
Recurrent Ovarian Cancer
Interventions
DRUG

Nuc-1031 and Carboplatin

Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)

Trial Locations (1)

W12 0HS

Garry Weston Cancer Centre, Hammersmith Hospital, London

All Listed Sponsors
lead

Imperial College Healthcare NHS Trust

OTHER

NCT02303912 - Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter